A Phase II Open Label, Uncontrolled, Multicenter Study to Evaluate Safety and Immunogenicity of a Surface, Antigen, Inactivated, Influenza Vaccine (Agrippal), Formulation 2012/2013, When Administered to Adult and Elderly Subjects

Trial Profile

A Phase II Open Label, Uncontrolled, Multicenter Study to Evaluate Safety and Immunogenicity of a Surface, Antigen, Inactivated, Influenza Vaccine (Agrippal), Formulation 2012/2013, When Administered to Adult and Elderly Subjects

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Dec 2015

At a glance

  • Drugs Influenza virus vaccine (Primary)
  • Indications Influenza virus infections
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Novartis Vaccines
  • Most Recent Events

    • 29 Sep 2012 New source identified and integrated (European Clinical Trials Database record: EudraCT2012-000063-24 ).
    • 31 Jul 2012 Actual initiation date 1 Jul 2012 added as reported by ClinicalTrials.gov.
    • 31 Jul 2012 Actual end date 31 Jul 2012 added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top